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Why aren’t we doing better in asthma: time for personalised
medicine?
Mike Thomas1,2,3,4
After decades of improvement, asthma outcomes have stalled. Mortality, hospitalisations, exacerbations and symptom control
remain sub-optimal. In controlled trials, most patients gain high levels of control, but in ‘real-life’ routine clinical practice most
patients do not. Avoidable factors are found in most asthma deaths and hospital admissions. This perspective paper considers and
contextualises the factors underlying poor asthma outcomes, and it suggests approaches that could improve the situation. Factors
discussed include severe, therapy-resistant disease and the role of new and upcoming pharmacological therapies in improving
outcomes. These are likely to be beneﬁcial when targeted on patients with severe disease and discrete phenotypic characteristics,
identiﬁed through biomarkers. However, for the majority of patients treated in the community, they are unlikely to be used widely,
and better use of current therapy classes will be more important. Non-adherence with regular inhaled corticosteroid treatment and
over-use of rescue bronchodilators are common, and many patients have poor inhaler technique. Self-management is frequently
poor, particularly in those with psychosocial disadvantages and co-morbidities. Communication between clinicians and patients is
sometimes poor, with failure to detect avoidable poor control and non-adherence, and failure to provide the necessary information
and education to support efﬁcient self-management. Strategies for improving monitoring and clinician–patient interactions to
allow personalised treatment are considered. These strategies have the potential to allow individual patient needs to be recognised
and efﬁcient targeting of the variety of effective pharmacological and non-pharmacological interventions that we possess, which
has the potential to improve both individual and population outcomes.
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INTRODUCTION
Despite effective therapies and an ongoing major investment on
the part of commissioners of services and of research, asthma
outcomes remain much worse in ‘real life’ than they could be, and
much worse than those achieved in controlled trials. This
perspectives paper aims to explore the complex web of factors
relating to pathology, patients, clinicians and health systems to
understand why we have stopped making progress and what we
can do to improve outcomes.
IMPROVEMENTS IN ASTHMA OUTCOMES HAVE STALLED
The remarkable improvements in asthma outcomes at the end of
the last century are among the great achievements of medicine.
Despite increasing prevalence,1 progressive improvements
occurred in hospitalisation, mortality, symptom control and quality
of life, through safe, effective medication and structured, proactive
care.2 Primary care generalists took on diagnosis and manage-
ment for most patients, with hospital-based specialist care
reserved for those with severe, therapy-resistant disease and poor
control. In hindsight, a misplaced sense of complacency arose.
Unfortunately, the new millennium has shown that such an
optimism was premature; asthma remains common, incurable and
outcomes have stalled.3 The disease burden remains huge,
resulting in similar levels of global health impairment as chronic
liver disease and schizophrenia.4 People continue to die and
experience severe, life-threatening attacks, which are frequently
avoidable.5 Most of them experience regular symptoms6 and
impaired ability to lead a full, productive life, resulting in large
direct and even larger indirect costs.7 The aims of management
are to reduce the impact on daily life (assessed by symptoms,
quality of life, health resource use and biomarkers of disease
activity) and the risk of adverse events (death, hospitalisation,
exacerbations and lung damage).8 Surveys have shown little or no
recent improvements in these outcomes in most developed
countries. For instance, mortality and hospitalisation rates in the
UK have not improved,9,10 with marked regional variations.11 The
majority of European patients continue to report signiﬁcant
symptoms,6 except countries prioritising asthma as a public health
problem.12 This has occurred despite a continual stream of new
licensed asthma products, and evidence that in tightly structured
clinical trial settings most patients can achieve good control.13
REASONS FOR POOR CONTROL: CLINICIAN-RELATED FACTORS
Although a huge effort has gone into producing and updating
asthma guidelines aimed largely at primary care practitioners,
clinician adherence with, and implementation of, guidelines is
frequently poor. Both diagnostic and prescribing patterns often do
not accord with actual care.9 For instance, guidelines recommend
that quality-assured spirometry should be performed on all
patients with suspected asthma to demonstrate obstruction and
reversibility; yet, objective lung function is often not measured at
all, and there are ongoing issues about the consistency of the
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quality of primary care spirometry.14 In cases of diagnostic
uncertainty, guidelines recommend the use of objective tests
such as measurement of bronchial hyper-reactivity or airways
inﬂammation, but in practice these are usually not currently
available to primary care clinicians in most health systems. Audits
of prescribing patterns in primary care clinicians often show
prescribing not in accord with guideline recommendations,15
including overprescribing of rescue bronchodilators, underuse of
inhaled corticosteroids (ICS), use of long-acting β2-agonists
(LABAs) as monotherapy and over-use of high doses of inhaled
ICS, particularly in children.16 These observations point to an
ongoing problem of dissemination of best practice and a likely
unawareness of guidelines and of spirometry performance or
interpretation in some practitioners, with a need for better
education and implementation strategies. It is also clear that many
patients ﬁnd it hard to engage with the systems of health care
that have been developed for asthma and other long-term
conditions that we are unable to cure. Although best care for
chronic diseases is proactive and involves self-management
education, many patients only attend for care when in a crisis.
Increasing numbers of patients have one or more long-term
conditions (multimorbidity), yet systems of care are usually
directed towards single conditions.17
REASONS FOR POOR CONTROL: THERAPY-RESISTANT DISEASE
The ‘stepped’ pharmacotherapy approach of asthma guidelines
perhaps encourages the belief that ‘stronger’ medication is
needed when the control is poor. Undoubtedly, some patients
have intrinsically severe, therapy-resistant disease, requiring more
effective treatments. However, even in this group, good quality
management (including effective education in self-management)
can often improve outcomes.18 The complexity and heterogeneity
of asthma is increasingly understood, particularly in difﬁcult
asthma, and the phenotypes19 and endotypes20 constituting the
asthma syndrome are better described, allowing speciﬁc groups to
be identiﬁed and targeted. However, severe asthma only affects
5–10%,9 and even here behavioural factors are common.21 Greater
understanding of biological abnormities with the use of biomar-
kers to deﬁne ‘responder’ groups allows targeting of expensive
treatments involving monoclonal antibodies. Anti-IgE is now a
part of care, and other mediator modulators are in late-phase
clinical trials.3 We can be optimistic that new treatments will soon
be available and, if used appropriately in dedicated ‘difﬁcult
asthma’ clinics with the necessary expertise, will be clinically
effective, as well as cost effective. Indiscriminate use in everyone
doing badly will not work. Psychosocial problems and non-
adherence are particularly common in this group, and the
involvement of primary care in coordinated, integrated multi-
disciplinary care is vital.22
Yet majority of patients rarely see a hospital pulmonologist, and
the control remains poor in those with ‘milder’ disease. Although
some may have severe disease, the likelihood is that for most of
them the reasons lie elsewhere. The UK National Review of Asthma
Deaths has shown that most deaths occurred in those considered
‘mild’.5 Few advances have occured in pharmacotherapy since
the leukotriene receptor antagonists, which have a role as an add-
on therapy. The mainstay of treatment remains ICS, with LABA as
ﬁrst choice add-on therapy. Newer ICS and LABA molecules show
some advantages in pharmacological properties, which may result
in limited incremental clinical improvements for some; however,
beneﬁts largely relate to medication classes. Once-daily dosing
may improve adherence and is preferred by patients, although the
beneﬁts over twice-daily regimes are not clear. The variety of
inhaler delivery devices grows, with some being easier to use and
to teach. However, despite the profusion of devices and molecules,
control remains far from optimal.
PATIENT-RELATED FACTORS IN POOR CONTROL: ADHERENCE
AND INHALER TECHNIQUE
Possibly the most common reasons for poor control are that many
patients either do not take treatment regularly or have poor
inhaler technique. Asthma is characterised by persistent airways
inﬂammation, although manifestations are at times subclinical.
The evidence for ICS is for regular use, and non-adherent patients
do not get into trials or are excluded as protocol violators.
However, in ‘real life’, adherence problems are ubiquitous. Regular
ICS protect against death,23 hospitalisation,24 exacerbations25 and
improve symptom control and quality of life. It is a source of
bewilderment to clinicians that many patients use ICS sporadically
or not at all. Adherence rates in asthma range from 30 to 70%,
with under 50% of children adhering to prescribed regimens.26
Non-adherence with ICS is associated with progressively worse
outcomes as use decreases,19,20 and it is common in asthma
deaths.5 It is estimated that each 25% increase in time without ICS
medication results in a doubling of the rate of asthma-related
hospitalisations.27 The reasons for non-adherence are complex,
and they include ‘non-intentional’ non-adherence—for example,
forgetting medication—and ‘intentional’ non-adherence—a con-
scious decision not to use medication as prescribed. From their
perspective, patients make a rational decision, based on their
assessment of health needs and risks. Many overestimate the
ICS-related risks and underappreciate the beneﬁts of regular
treatment. Some worry that the ICS ‘wear off’ with regular use
despite the lack of objective evidence of tachyphylaxis. The
relatively slow time course of ICS leads some to conclude that they
do not work for them, particularly in comparison with the rapidly
perceptible effects of bronchodilators. As many patients experi-
ence asthma as being intermittent, some only recommence ICS
when symptomatic. LABAs are an effective add-on therapy, but
they are unlicensed and associated with the risk of adverse events
and even death when used without ICS.28 Unfortunately, this
pattern of use continues to occur in real life, sometimes with tragic
results.5
We encourage self-management, which is clearly necessary in a
variable long-term condition. However, we fail to appreciate that
non-adherence is also a form of self-management, although based
on misunderstandings and inadequate information, and thus it is
fundamentally a problem of inadequate patient–clinician com-
munication. Some clinicians ‘blame’ patients for non-adherence,
considering it irresponsible, a breach of the doctor–patient
relationship and beyond their remit to remedy;29 yet, it is likely
that adherence would increase if the rationale was explained
in a way they understood and assimilated. Self-management
education,30 involving patients in decisions,31 simpliﬁed treatment
regimes32 and discussion of non-adherence when detected (for
example, through the monitoring of reﬁll prescription rates)33 all
improve adherence and outcomes. There is a growing interest in
using IT to support self-management and education.34 To
progress, we have to work in partnership with patients, respecting
their autonomy and recognising that they will self-manage most
of the time whatever we do. Our responsibility is to ensure that
their decisions are based on good information.
Correct inhaler technique is necessary for medication delivery
and again the guideline evidence comes from fully trained
patients demonstrating good technique. Unfortunately, in ‘real
life’, many patients use their inhaler badly—most will make some
errors and many make ‘critical errors’ that result in little or no
medication delivery. It is unsurprising that there is a relationship
between the number of errors and asthma control.35 Some
inhalers are easier than others, and often the least expensive
devices are hardest to use and teach.36 Ideally, all would be
educated in inhaler technique by suitably qualiﬁed professionals
when ﬁrst prescribed, and checked at least annually and after loss
of control. However, once again in ‘real life’ this does not happen
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frequently—some are never instructed, other than from printed
packaging inserts, and many are not periodically reassessed and
corrected.37 Indeed, some clinicians cannot demonstrate the
correct technique themselves. It is incumbent on the prescriber
to ensure correct technique, either personally or delegating to
colleagues—for example, nurses or pharmacists.
PATIENT-RELATED FACTORS IN POOR CONTROL:
PSYCHOSOCIAL AND BEHAVIOURAL FACTORS
As an incurable, life-long condition, asthma heavily affects well-
being. Friends, colleagues and sometimes health professionals can
fail to appreciate fully the impact asthma has on people’s lives.
The recurrent and unpredictable experience of having to struggle
to breathe is frightening and disturbing, and it can undermine
well-being and stability. Those with other life stressors, such as
co-morbidity, psychosocial disadvantage or with genetically or
environmentally programmed lack of resilience, may experience
symptoms as more distressing. All clinicians know that some
patients cope better with illness than others. Some do well despite
objectively severe asthma, whereas others have high symptom
levels and multiple subjective problems despite apparently mild
disease. Patient-reported outcomes, such as symptoms and
quality of life, correlate poorly with ‘objective’ physiological and
pathological parameters of disease control,38,39 although they are
strongly correlated with psychosocial measures.40 Socioeconomic
factors, multimorbidities and psychological state41 have a strong
relationship with asthma outcomes of every type, and anxiety is
the strongest independent predictor of the unpleasantness of
breathlessness for a given degree of brochoconstriction.42
Symptoms, quality of life, health resource use, exacerbation
frequency and even mortality are independently related to
psychological state, with one study reporting psychiatric
co-morbidity accounting for 29% of symptom variance.43
Psychological dysfunction is six times as common in people
with asthma,37 and asthma-related quality of life correlates more
closely with psychological and social status than lung function or
treatment step.44 The underlying mechanisms probably relate
to a variety of overlapping biological and behavioural factors.
Functional neuroimaging has shown that brain structures
mediating breathlessness are closely related anatomically and
functionally to those processing emotions,45 and emotional state
may inﬂuence immunological responses.46 Anxiety is associated
with impaired self-management.47 Hyperventilation and dysfunc-
tional breathing are associated with anxiety, occur in asthma and
may trigger bronchoconstriction and asthma-like symptoms,48
with simple breathing control exercises improving symptoms and
quality of life.49 A certain amount of anxiety is natural and
inevitable with distressing symptoms, such as dyspnoea, and it
can promote appropriate responses such as seeking help or using
necessary medication, but excessive anxiety or inappropriate
responses can result in a ‘negative feedback’ situation of
worsening symptoms leading to further emotional and cognitive
distress.
MOVING FORWARD: HOW CAN WE DO BETTER?
We need to get smarter in asthma. We do need new treatments,
but we can do much better with what we already have. We require
appropriately trained primary care professionals who are
adequately resourced to provide quality asthma care. The ﬁrst
requirement is to detect poor control and risk. Unfortunately,
patients may not volunteer how symptomatic they are, having
grown accustomed to this over the years, and clinicians may not
ask probing-enough questions. Structured reviews incorporating
objective symptom assessment (ideally using validated question-
naires) will often uncover unmet need. Risk stratiﬁcation to
identify those at higher risk of attacks is feasible and can lead
to better outcomes.50 Assessing rescue bronchodilator use
(for example, by repeat prescription monitoring) is often revealing.
Having uncovered poor control and risk, the next step is to
understand why. Stepping up pharmacotherapy may be right for
some patients, but addressing adherence, technique, rectifying
self-management deﬁciencies and identifying co-morbidities
(for example, anxiety, rhinitis, obesity, smoking) may be helpful
in others. Simple behavioural techniques such as breathing
exercises or anxiety management may help appropriately
identiﬁed patients. For those needing increased treatment, better
characterisation may lead to more rational and targeted treatment
—for example, biomarker evidence of ongoing inﬂammation may
point to the need for more effective anti-inﬂammatory treatment
rather than increased bronchodilatation.51 Current guidelines
provide a stepped approach for all patients as if they were
similar, based on group mean data from clinical trials. However,
responder analyses reveal remarkable heterogeneity of response
to different treatments.52 The future lies in a stratiﬁed, individua-
lised approach to asthma care;53 this is starting to occur at the
severe end of the spectrum, but may be equally feasible and cost
effective in wider asthma populations. We have a range of
assessment options, including monitoring medication use, vali-
dated patient-reported outcome measures and simple, near-
patient objective tests and a variety of treatment options (both
pharmacological and non-pharmacological) that we need to
target appropriately. Having spent years dissecting asthma and
unravelling its complexity, we now need to put this information
together into coherent, patient-orientated personalised care.
CONCLUSION
Although asthma outcomes have stalled, we should use this as a
spur to changing models of care rather than as a source of gloom.
Our ever-increasing knowledge of the complexity and hetero-
geneity of asthma, together with a better understanding of how
patient and clinician behaviour can be modiﬁed to make better
use of the resources we do possess, allows us potential new
avenues in care. It is unlikely in the foreseeable future that we can
‘cure’ asthma, but we should be able to characterise our patients
better, in particular those who, for one reason or another, are not
doing well, and for most there will be effective strategies for
improving outcomes. However, the most effective intervention(s)
will vary greatly between patients, and a ‘one size ﬁts all’ approach
will no longer sufﬁce. As with other long-term conditions, we need
to help our patients cope with the diverse consequences of
having an illness that we can control but not take away.
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